Exchange: NASDAQ·Updated 04:49 AM EDT
Latest Earnings Results: Q2 '26

Reported: Aug 10

Estimated EPS

-$0.89

Reported EPS

-$0.99

Surprise

-10.98%

Estimated Rev

$221.11M

Reported Rev

$216.35M

Surprise

-2.15%

• Reported GAAP EPS of -$0.99 down -2.06% YoY • Reported revenue of $218.38M up 45.54% YoY • Axsome Therapeutics believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan, though no specific financial targets were provided.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.49
--
--
N/A
Q2 '26
-$0.89
-$0.99
-10.98%
MISSED
Q1 '26
-$0.81
-$1.26
-54.69%
MISSED
Q4 '25
-$0.69
-$0.56
19.13%
BEAT
Q3 '25
-$0.86
-$0.94
-9.73%
MISSED

Advertisement|Remove ads.